Anthropic just made its most serious move yet into the life sciences, and it chose a deliberately unglamorous entry point. The company unveiled Claude Science on June 30 at a San Francisco event, pitching an AI-powered research workbench built for computational biology and drug discovery, with a specific focus on diseases that the pharmaceutical industry has largely written off as not worth the trouble.
What Claude Science actually does
The platform connects to more than 60 scientific tools and databases, including PubMed and Jupyter, and is capable of running tasks like single-cell RNA sequencing and CRISPR design autonomously. In English: it can handle the kind of data-heavy, multi-step laboratory workflows that would normally require a team of specialists and weeks of manual effort.
Early demonstrations showed the platform independently identifying potential treatments for phenylketonuria, a rare metabolic disorder caused by the buildup of an amino acid called phenylalanine. The beta version is currently available to paid Claude users on macOS and Linux. Anthropic is using the rollout to build feedback loops with researchers before pushing deeper into biopharma workflows.
Anthropic also announced an internal drug discovery program running alongside the platform. The company is not just selling tools. It is doing the research itself, focused on the same neglected and rare disease categories.
